Effect of the Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) on Corneal Endothelial Wound Healing.

摘要: PURPOSE Ripasudil (Glanatec), a selective rho-associated coiled coil-containing protein kinase (ROCK) inhibitor, was approved as glaucoma and ocular hypertension treatment in Japan 2014. The purpose of this study to investigate the feasibility using ripasudil eye drops treat corneal endothelial injuries. METHODS Cultured human cells (HCECs) were treated with ripasudil, 5-bromo-2'-deoxyuridine (BrdU) incorporation evaluated by ELISA. A rabbit damage model also created mechanically scraping endothelium, followed topical drop application for 2 weeks. anterior segment slit-lamp microscopy, central thickness measured ultrasound pachymetry. Corneal specimens phalloidin staining immunohistochemical analysis antibodies against Ki67, N-cadherin, Na+/K+-ATPase. RESULTS Many more BrdU-positive observed among HCECs (0.3-30 μM) than control HCECs. Ripasudil-treated eyes showed 91.5 ± 2.0% Ki67-positive after 48 hours, whereas 52.6 1.3%. Five six corneas became transparent ripasudil-treated eyes, zero eyes. Regenerated cell densities higher vehicle. Eyes expressed N-cadherin Na+/K+-ATPase almost all CECs, expression decreased CONCLUSIONS promoted wound healing, supporting its development treating acute due surgeries, especially cataract surgery.